Merck will gain a worldwide licence to research, develop and commercialise small molecule candidates. Credit: Katherine Welles/Shutterstock.com.

Astex Pharmaceuticals and Merck (MSD) have expanded their collaboration to identify small molecule candidates to target different forms of the p53 tumour suppressor protein for cancer treatment.

Under the research collaboration and licence agreement, Astex will leverage its fragment-based drug discovery platform to develop these compounds.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

They will then be provided to MSD for further optimisation and preclinical development.

Astex Pharmaceuticals president and CEO Harren Jhoti stated: “This new alliance builds on our existing productive collaboration and allows us to combine our expertise and assets with MSD’s wide-ranging oncology capabilities.”

Merck will gain an exclusive worldwide licence for the research, development and commercialisation of the candidates to be developed under the partnership.

Astex will receive $35m in an upfront payment and subsequent milestone payments totalling $500m per programme, along with tiered royalties on product sales.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MSD will be responsible for funding all activities related to the future research and development of lead candidates and the commercialisation of products across the globe.

MSD discovery and translational medicine senior vice-president George Addona stated: “At MSD, we are committed to driving innovation with the goal of improving outcomes for patients with cancer.

“We look forward to building on our collaboration with the Astex team to advance this potentially impactful area of oncology research.”

In June 2023, Merck extended its peptide collaboration with contract research organisation IRBM.